|
US20110236476A1
(en)
|
2008-09-02 |
2011-09-29 |
Amarin Corporation Plc. |
Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
|
|
MX2011004077A
(es)
|
2008-10-17 |
2011-08-17 |
Metabolex Inc |
Metodos para reducir particulas de ldl densas, pequeñas.
|
|
SG10201605794PA
(en)
|
2009-04-29 |
2016-09-29 |
Amarin Pharmaceuticals Ie Ltd |
Stable Pharmaceutical Composition And Methods Of Using Same
|
|
WO2010127099A2
(en)
|
2009-04-29 |
2010-11-04 |
Amarin Corporation Plc |
Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
|
|
CN108096209A
(zh)
|
2009-06-15 |
2018-06-01 |
阿马里纳制药公司 |
在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
|
|
WO2011038122A1
(en)
|
2009-09-23 |
2011-03-31 |
Amarin Corporation Plc |
Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
|
|
US9719068B2
(en)
|
2010-05-06 |
2017-08-01 |
Children's Hospital Medical Center |
Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
|
|
EP2646013A4
(en)
|
2010-11-29 |
2014-03-26 |
Amarin Pharma Inc |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
|
EP2775837A4
(en)
|
2011-11-07 |
2015-10-28 |
Amarin Pharmaceuticals Ie Ltd |
METHODS OF TREATING HYPERTRIGLYCERIDEMIA
|
|
JP6307442B2
(ja)
|
2012-01-06 |
2018-04-04 |
アマリン ファーマシューティカルス アイルランド リミテッド |
対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法
|
|
SMT202500326T1
(it)
|
2012-06-29 |
2025-11-10 |
Amarin Pharmaceuticals Ie Ltd |
Estere etilico dell’acido eicosapentaenoico per l’uso nella riduzione del rischio di ictus non fatale in un soggetto in terapia con statine
|
|
US20150265566A1
(en)
|
2012-11-06 |
2015-09-24 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
|
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
|
US9814733B2
(en)
*
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
|
US10272058B2
(en)
|
2014-03-20 |
2019-04-30 |
Cymabay Therapeutics, Inc. |
Treatment of intrahepatic cholestatic diseases
|
|
CN106102734B
(zh)
|
2014-03-20 |
2019-05-14 |
西玛贝医药公司 |
肝内胆汁淤积性疾病的治疗
|
|
KR102374499B1
(ko)
|
2014-04-11 |
2022-03-14 |
사이머베이 쎄라퓨틱스, 인코퍼레이티드 |
Nafld 및 nash 의 치료
|
|
US10174289B2
(en)
|
2014-05-28 |
2019-01-08 |
Children's Hospital Medical Center |
Methods and systems for converting precursor cells into gastric tissues through directed differentiation
|
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
|
WO2015195662A1
(en)
|
2014-06-16 |
2015-12-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
|
|
US11584916B2
(en)
|
2014-10-17 |
2023-02-21 |
Children's Hospital Medical Center |
Method of making in vivo human small intestine organoids from pluripotent stem cells
|
|
MX2017012319A
(es)
*
|
2015-03-26 |
2018-05-11 |
T3D Therapeutics Inc |
Metodos para tratar enfermedad hepática utilizando derivados de acido indano acético.
|
|
CN115025079A
(zh)
|
2015-04-28 |
2022-09-09 |
普罗诺瓦生物医药挪威公司 |
结构增强的含硫脂肪酸在预防和/或治疗非酒精性脂肪性肝炎中的用途
|
|
WO2017049157A1
(en)
*
|
2015-09-18 |
2017-03-23 |
Duke University |
Methods and compositions for the treatment of steatosis-associated disorders
|
|
WO2017139708A1
(en)
|
2016-02-10 |
2017-08-17 |
Synlogic, Inc. |
Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
|
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
|
US12053445B2
(en)
|
2016-03-31 |
2024-08-06 |
Genfit |
Methods of treatment of cholestatic diseases
|
|
CA3016641A1
(en)
|
2016-05-05 |
2017-11-09 |
Children's Hospital Medical Center |
Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
|
|
GB201614455D0
(en)
*
|
2016-08-24 |
2016-10-05 |
Univ Oxford Innovation Ltd |
Biomarkers
|
|
KR102546194B1
(ko)
*
|
2016-11-04 |
2023-06-21 |
칠드런즈 호스피탈 메디칼 센터 |
간 유사 장기 조성물 및 이를 제조 및 사용하는 방법
|
|
US10493363B2
(en)
*
|
2016-11-09 |
2019-12-03 |
Activision Publishing, Inc. |
Reality-based video game elements
|
|
WO2018106628A1
(en)
|
2016-12-05 |
2018-06-14 |
Children's Hospital Medical Center |
Colonic organoids and methods of making and using same
|
|
WO2018191673A1
(en)
|
2017-04-14 |
2018-10-18 |
Children's Hospital Medical Center |
Multi donor stem cell compositions and methods of making same
|
|
WO2018204775A1
(en)
|
2017-05-05 |
2018-11-08 |
Hepanova, Inc. |
Amino-aryl-benzamide compounds and methods of use thereof
|
|
WO2018213663A1
(en)
|
2017-05-19 |
2018-11-22 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject having reduced kidney function
|
|
US10512622B2
(en)
|
2017-07-14 |
2019-12-24 |
Cymabay Therapeutics, Inc. |
Treatment of intrahepatic cholestatic diseases
|
|
JP2020533339A
(ja)
|
2017-09-13 |
2020-11-19 |
ノバルティス アーゲー |
Ｆｘｒアゴニストを含む組合せ
|
|
EP3694603A4
(en)
|
2017-10-10 |
2021-07-14 |
Children's Hospital Medical Center |
ESOPHAGUS TISSUE AND / OR ORGANOID COMPOSITIONS AND METHOD FOR MANUFACTURING THEREOF
|
|
US11260066B2
(en)
|
2017-10-27 |
2022-03-01 |
Samyang Corporation |
Inhibiting reduction of lean body mass and inhibiting accumulation of liver fat by administering allulose
|
|
SG11202005007VA
(en)
|
2017-12-06 |
2020-06-29 |
Basf As |
Fatty acid derivatives for treating non-alcoholic steatohepatitis
|
|
WO2019126626A1
(en)
|
2017-12-21 |
2019-06-27 |
Children's Hospital Medical Center |
Digitalized human organoids and methods of using same
|
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
|
WO2020023245A1
(en)
|
2018-07-26 |
2020-01-30 |
Children's Hospital Medical Center |
Hepato-biliary-pancreatic tissues and methods of making same
|
|
SG11202102431YA
(en)
|
2018-09-12 |
2021-04-29 |
Childrens Hospital Med Ct |
Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
|
|
EP3700518A4
(en)
|
2018-09-24 |
2020-12-16 |
Amarin Pharmaceuticals Ireland Limited |
METHODS OF REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT
|
|
BR112021009038A2
(pt)
*
|
2018-11-16 |
2021-08-10 |
Cymabay Therapeutics, Inc. |
tratamento combinado de nafld e nash
|
|
EP3880187A1
(en)
|
2018-11-16 |
2021-09-22 |
CymaBay Therapeutics, Inc. |
Treatment of obesity and its complications
|
|
CN121081472A
(zh)
|
2018-12-13 |
2025-12-09 |
拓臻股份有限公司 |
一种THRβ受体激动剂化合物及其制备方法和用途
|
|
CA3141814A1
(en)
|
2019-05-31 |
2020-12-03 |
Children's Hospital Medical Center |
Shaped organoid compositions and methods of making same
|
|
EP3976066A4
(en)
|
2019-05-31 |
2023-06-28 |
Children's Hospital Medical Center |
Methods of generating and expanding hematopoietic stem cells
|
|
EP4017875A4
(en)
|
2019-08-23 |
2023-05-03 |
Terns Pharmaceuticals, Inc. |
THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS
|
|
JP2022548250A
(ja)
|
2019-09-12 |
2022-11-17 |
ターンズ・ファーマシューティカルズ・インコーポレイテッド |
甲状腺ホルモン受容体ベータアゴニスト化合物
|
|
CN114980973A
(zh)
|
2019-11-12 |
2022-08-30 |
阿马里纳药物爱尔兰有限公司 |
降低心房纤颤和/或心房扑动受试者心血管事件风险的方法
|
|
WO2021097034A1
(en)
|
2019-11-14 |
2021-05-20 |
Cymabay Therapeutics, Inc. |
Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases
|
|
WO2021097027A1
(en)
|
2019-11-14 |
2021-05-20 |
Cymabay Therapeutics, Inc. |
Seladelpar for use in the treatment of alcoholic liver disease
|
|
US20210379043A1
(en)
*
|
2020-05-13 |
2021-12-09 |
Terns Pharmaceuticals, Inc. |
Combination treatment of liver disorders
|
|
EP4326244A4
(en)
|
2021-04-21 |
2025-03-19 |
Amarin Pharmaceuticals Ireland Limited |
METHODS TO REDUCE THE RISK OF HEART FAILURE
|
|
US20240216312A1
(en)
*
|
2021-05-11 |
2024-07-04 |
Genfit |
Ppar-agonists for use in the treatment of liver failure
|